Basic research for development of CTL-inducible vaccine against West Nile virus using recombinant E protein

利用重组E蛋白开发抗西尼罗病毒CTL诱导疫苗的基础研究

• 批准号: 19590604
• 负责人: MASAKI Hideyuki
• 金额: $ 2.91万
• 依托单位: Kinki University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2007
• 资助国家: 日本
• 起止时间: 2007 至 2010
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-19590604/
• 关键词: ウエストナイルウイルス; E蛋白質; 成分ワクチン; 組換えワクチン; CTL; cross-presentation; 中和抗体; 感染防御; 感染防護

West Nile virus (WNV) is the human-infectious virus, which sometimes causes lethal encephalitis/meningitis, and the vaccine for human use has not been developed yet. Based on the findings concerning its relative viruses, it is anticipated that the envelope (E) protein should induce protective immunity. In the present study, we have established several recombinant WNV E protein expression systems and the CTL target cells in order to develop the recombinant component vaccine against WNV infection, which induces not only neutralizing antibody but also CTL, using recombinant WNV E protein combined with cross-presentation inducing adjuvant.

西尼罗河病毒（West Nile virus，WNV）是一种人类感染性病毒，有时会引起致命的脑炎/脑膜炎，但目前还没有研制出人用疫苗。基于关于其相关病毒的发现，预期包膜（E）蛋白应诱导保护性免疫。本研究建立了几种重组WNV E蛋白表达系统和CTL靶细胞，以期利用重组WNV E蛋白和交叉呈递诱导佐剂，研制出既能诱导中和抗体，又能诱导CTL的重组WNV组分疫苗。